Are These Buying Opportunities? Ampio Pharmaceuticals Inc (AMPE) and RXi Pharmaceuticals Corp (RXII)

Posted by Saimoon March 26, 2015 0 Comment 1300 views


New York, NY – GDP INSIDER  –  03/26/2015.

This article discusses two companies: Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) and RXi Pharmaceuticals Corp (NASDAQ:RXII)

Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) fell back yesterday with the stock dropping 13.36% or $1.15 to close at $7.46 with more than 1.398 million shares changing hands, compared to its three month average trading volume of 0.811 million. The developer of therapies to treat prevalent inflammatory conditions had been riding high of late, with the stock edging close to its 52 week high of $9.01 on Tuesday. The sell off began on no major news, but Ampio Pharmaceuticals Inc’s RSI has been well into the seventies for most of the month, indicating that the stock was probably overvalued. Investors finally took the opportunity to take their profits as the stock was not looking to break through its $8.80 resistance level. With a bearish MACD crossover looking likely, the stock could fall further still, but should be approaching its support level at about $7.40 making it a hold and potential buy.

Is Ampio Pharmaceuticals Inc Going To Bounce Back? Take A Look At The Technical Indicators With Our Free AMPE Analysis.

RXi Pharmaceuticals Corp (NASDAQ:RXII) continued to fall yesterday with the stock losing an additional 12.22% or $0.11 to close at $0.79 on heavy trading of 2.360 million shares, compared to its three month average trading volume of 0.469 million shares. RXi Pharmaceuticals Corp has not been doing particularly well in the current year, with the stock trading about 30% under the S&P 500. With this week’s losses, the stock has now lost 50.61% so far this year, compared to the S&P 500 which has gained 0.10% over the same period. The biotechnology company focused on discovering, developing and distributing RNA interference therapies is now starting to look undervalued with RSI of 29.48 and today’s significant decline seems sector-wide, which may mean that the stock may well recover slightly in the near term. It is still a risky buying opportunity, but one that may be worth it over the medium term.

Do RXi Pharmaceuticals Corp’s Fundamentals Support Significant Medium Term Gains? Click Here For Free RXII Analysis.

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment